Print

NuVasive, Inc. (NUVA) to Exhibit at ISASS 2013  
3/27/2013 10:31:31 AM

SAN DIEGO, CA--(Marketwire - March 27, 2013) - NuVasive, Inc. (NASDAQ: NUVA), a medical device company focused on developing minimally disruptive surgical products and procedures for the spine, is excited to announce their participation at the 2013 International Society for the Advancement of Spine Surgery (ISASS) Conference from Tuesday, April 2nd, to Saturday, April 6th, 2013, at the Vancouver Convention Centre in Vancouver, Canada, booth #212.

ISASS is one of the most widely attended conferences by spine surgeons throughout the world due to the robust weeklong agenda that includes exhibits featuring innovative devices and techniques, a cadaver course, scientific presentations, and exclusive educational opportunities.

"NuVasive is pleased to exhibit our innovative technologies and comprehensive spine portfolio at ISASS," said Pat Miles, NuVasive President of Global Products and Services. "This year, we are excited to introduce surgeons to several game-changing new products and procedures, such as the PCM® Cervical Disc and Precept™ for MAS® Posterior Fixation. As well, our XLIF®, ALIF, and posterior fixation solutions will be featured in cadaver courses organized by ISASS, providing surgeons hands-on educational experiences and opportunities to become more familiar with NuVasive's full product portfolio."

NuVasive is scheduled to participate in the following events at ISASS:

  • NuVasive Exhibit Booth #212: The NuVasive exhibit booth will feature a number of innovative, minimally disruptive products and procedures including: XLIF®, Precept™, MAS® PLIF, Armada®, Biologics, our comprehensive cervical portfolio including the PCM® Cervical Disc, and our NVM5®system.

  • NuVasive Sponsored Workshop: A lunch workshop will be held from 12:00 PM to 1:30 PM on Wednesday, April 3rd, in Room 7 to discuss Maximum Access Surgery (MAS®) techniques for complex pathologies such as spondylolisthesis and degenerative scoliosis, kyphosis and sagittal balance, and tumor and trauma.

  • ISASS Organized Cadaver Course: NuVasive will participate in cadaver courses on April 5th from 3:30 PM to 5:30 PM (didactic session) and on April 6th from 7:00 AM to 1:00 PM (cadaver lab).

  • Clinical Papers: NuVasive solutions will be featured in 14 invited podium presentations and numerous posters that include the latest research on our minimally invasive portfolio and advanced biologics.

For more information on ISASS 2013 please visit:
http://www.isass.org/h/isass13_conference_program.html

For NuVasive Press Materials please visit: http://www.nuvasive.com/about-us/newsroom/

About ISASS
The International Society for the Advancement of Spine Surgery is an international, scientific and educational society organized to discuss and assess existing strategies and innovative ideas in the clinical and basic sciences related to spine surgery and to enhance patient care.

About NuVasive
NuVasive is a medical device company focused on developing minimally disruptive surgical products and procedurally integrated solutions for the spine. The Company is the 4th largest player in the $8.2 billion global spine market. NuVasive's principal product offering is based on its Maximum Access Surgery, or MAS® platform. The MAS platform combines several categories of solutions that collectively minimize soft tissue disruption during spine surgery with maximum visualization and safe, easy reproducibility for the surgeon: a proprietary software-driven nerve avoidance system and intra-operative monitoring support; MaXcess®, a unique split-blade retractor system; a wide variety of specialized implants; and several biologic products to aid in the spinal fusion process. MAS significantly reduces surgery time and returns patients to activities of daily living much faster than conventional approaches. Having redefined spine surgery with the MAS platform's lateral approach, known as eXtreme Lateral Interbody Fusion, or XLIF®, NuVasive has built an entire spine franchise. With over 80 products today spanning lumbar, thoracic and cervical applications, the Company will continue to expand and evolve its offering predicated on its R&D focus and dedication to outstanding service levels supported by a culture of Absolute Responsiveness®.

NuVasive cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements that involve risks, uncertainties, assumptions and other factors which, if they do not materialize or prove correct, could cause NuVasive's results to differ materially from historical results or those expressed or implied by such forward-looking statements. The potential risks and uncertainties are described in NuVasive's press releases and periodic filings with the Securities and Exchange Commission. NuVasive's public filings with the Securities and Exchange Commission are available at www.sec.gov. NuVasive assumes no obligation to update any forward-looking statement to reflect events or circumstances arising after the date on which it was made.


Investor Contact:
Stephan Ogilvie
VP, Corporate Development & Investor Relations
NuVasive, Inc.
201-322-6515
Email Contact

Media:
Nicole Collins
NuVasive, Inc.
858-909-1907
Email Contact


//-->